Sermorelin 5 mg Dosage Chart and Protocol

Plan based on an 8–week daily protocol with gradual titration (56 injections total).

• Peptide Vials (Sermorelin, 5 mg each):
  • 8 weeks (total ~19.6 mg consumed): 4 vials (20 mg total)
  • 12 weeks (similar daily range): 6–7 vials
  • Tip: Have 1 extra vial as backup in case of spillage or loss.
• Insulin Syringes (U‑100):
  • Per week: 7 syringes (1/day)
  • 8 weeks: 56 syringes (recommend 1 × 100‑count box)
  • 12 weeks: 84 syringes (1 × 100‑count box)
  • Preferred: 0.3–0.5 mL size with 28G–31G needle, 5/16″ to 1/2″ length for subcutaneous use.
• Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
  • 8 weeks (4 vials): 12 mL → 2 × 10 mL bottles
  • 12 weeks (7 vials): 21 mL → 3 × 10 mL bottles
  • Contains benzyl alcohol preservative; do not use if allergic.
• Alcohol Swabs: One for the vial stopper + one for the injection site each day.
  • Per week: 14 swabs (2/day)
  • 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
  • 12 weeks: 168 swabs → recommend 2 × 100‑count boxes

Sharps Container: One puncture‑proof disposal container for used needles (sufficient for 56+ syringes).

Sermorelin 5 mg

View Supplier

U-100 syringes

View Supplier

Bacteriostatic water

View Supplier

Alcohol swabs

View Supplier

• Reconstitute: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration.
• Typical daily range: 200–500 µg once daily at bedtime (gradual titration).
• Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 µg on a U‑100 insulin syringe.
• Storage: Lyophilized: refrigerate at 2–8 °C (36–46 °F); after reconstitution, refrigerate at 2–8 °C (36–46 °F) and follow the exact product’s labeled use-by instructions^[4].

Sermorelin is a synthetic growth hormone–releasing hormone (GHRH) analog that stimulates endogenous pituitary GH secretion^[1]. Originally approved for pediatric growth hormone deficiency, it is studied for adult off‑label use to support physiologic GH output and IGF‑1 levels^[2]. This educational protocol presents a once‑daily subcutaneous approach administered at bedtime to align with natural nocturnal GH release^[3].

Concise summary of the once‑daily nightly regimen.

• Goal: Stimulate endogenous pituitary GH release to support physiologic IGF‑1 levels and anabolic processes^[1][2].
• Schedule: Daily subcutaneous injections at bedtime for 3–6 months (pediatric trials ran 6–12 months; adult use is off‑label)^[1].
• Dose Range: 200–500 µg daily (adult research range; pediatric: 30 µg/kg nightly)^[1][2].
• Reconstitution: 3.0 mL per 5 mg vial (~1.67 mg/mL) for accurate unit measurements.
• Storage: Lyophilized refrigerated; reconstituted refrigerated with use-by determined by the exact product’s instructions^[4].

Suggested nightly titration approach for adult off‑label use.

• Start: 200 µg nightly at bedtime; increase by ~100 µg every 1–2 weeks as tolerated.
• Target: 300–500 µg nightly by Weeks 5–8 (adjust based on IGF‑1 response).
• Frequency: Once per day (subcutaneous, preferably before sleep)^[3].
• Cycle Length: 3–6 months typical for adult research use; pediatric trials ran 6–12 months^[1].
• Timing: Bedtime administration leverages natural nocturnal GH pulse; rotate injection sites systematically^[7].

Proper storage preserves peptide potency and sterility.

• Lyophilized: Store at 2–8 °C (36–46 °F) in dry, dark conditions^[2]. Do not freeze dry powder; check expiration date.
• Reconstituted: Refrigerate at 2–8 °C (36–46 °F)^[4]; do not freeze mixed solution^[4]. Follow product-specific use-by and sterile-handling instructions; bacteriostatic water alone does not establish a shelf life.
• Allow vials to reach room temperature before reconstituting to aid dissolution; inspect solution before each use (should be clear and colorless)^[2].
• Always use aseptic technique: swab stopper with alcohol before each draw; use new sterile needle and syringe per injection^[2].

A Sermorelin 5 mg dosage page has to separate the amount in the vial from the amount represented by a syringe marking. The vial contains 5 mg before dilution. Adding the displayed 3.0 mL final volume produces approximately 1.67 mg/mL, or 1,667 mcg/mL. On a U-100 syringe, 1 unit is 0.01 mL, so each unit represents about 16.7 mcg at this concentration.

A Sermorelin dosage calculator must use both the actual vial strength and the final liquid volume; one syringe unit is a volume marking, not a fixed peptide amount. The conversion is 1,667 mcg/mL × 0.01 mL per unit ≈ 16.7 mcg per unit.

The Sermorelin dosage chart also shows why theoretical vial yield changes with the amount represented by each administration. Dividing 5,000 mcg by 200, 300, 400, or 500 mcg gives 25, 16.7, 12.5, or 10 administrations before handling loss. This arithmetic explains the displayed conversion; it does not establish a recommended amount or change the schedule above.

The linked supplier listing identifies the 5 mg product and image used for this strength-specific page. It is product provenance, not scientific evidence for a dosing claim.^[13]

The active compound is a synthetic peptide corresponding to the first 29 amino acids of growth hormone-releasing hormone. It binds GHRH receptors on pituitary somatotroph cells and signals the pituitary gland to release endogenous growth hormone. It is therefore a growth hormone secretagogue, not recombinant human growth hormone itself.^[1][6]

A response requires a functional pituitary, and the release of growth hormone remains influenced by normal hypothalamic and pituitary feedback. The resulting growth hormone secretion can affect circulating IGF-1, but it should not be treated as equivalent to administering exogenous hormone.^[6]

Research discussions often use phrases such as natural growth hormone and growth hormone production loosely. The more precise description is stimulation of endogenous GH release. Claims about muscle mass, body composition, weight loss, recovery, or anti-aging outcomes require direct clinical evidence in the population discussed; mechanism alone does not prove those outcomes.

The strongest published treatment evidence for sermorelin acetate concerns children with idiopathic growth hormone deficiency. A review reported increased height velocity in some prepubertal children while also noting that final adult height and direct comparison with somatropin were not established.^[1] FDA records document the historical Geref approval for pediatric growth hormone deficiency, not a general adult body-composition indication.^[11]

Adult evidence answers narrower questions. A dose-response study found that injected GHRH(1-29)NH2 produced acute growth hormone responses in adult men, supporting biological activity but not a long-term adult dosing schedule.^[9] A small retrospective report described higher IGF-1 during a combination of this analog and two growth hormone-releasing peptides. Because the compounds were combined and only 14 men met strict inclusion criteria, that study cannot isolate one ingredient’s effect.^[10]

For that reason, adult Sermorelin injections should not be described as having one universally validated starting amount, optimal protocol, or predictable outcome. The schedule on this page remains an educational calculation model and is unchanged by this evidence update.

Common side effects of Sermorelin in published information have most often involved temporary injection-site pain, redness, or swelling. Headache, flushing, dizziness, drowsiness, hives, and allergic reactions have also been described less often.^[5]

Published pediatric information and prescribing references discuss growth hormone levels, IGF-1 response, thyroid status, and clinical growth measures. Those monitoring concepts do not supply a self-directed adjustment rule for a research vial. A qualified healthcare provider or healthcare professional would interpret medical testing and contraindications in a clinical setting; this page supplies calculation context and research evidence, not individualized treatment instructions.

Preparation quality is separate from peptide amount. Use aseptic handling, a new sterile syringe for each administration, and the storage conditions already shown. Do not use a cloudy, discolored, damaged, or contaminated solution. Product-specific instructions determine preparation and discard conditions; bacteriostatic water alone does not establish stability for every compounded sermorelin acetate product.^[4][7]

Is 5 mg the administration amount or the vial strength?

It is the total peptide mass in the vial. The amount represented by a syringe marking depends on concentration after dilution. Milligrams in the vial and micrograms represented by an administration are different measurements.

How is the U-100 conversion calculated?

At approximately 1.67 mg/mL, 0.01 mL contains about 16.7 mcg. Because one U-100 unit marks 0.01 mL, the arithmetic is approximately 16.7 mcg per unit. The chart lists units and mL together so readers do not have to infer one from the other.

Does this page change the existing schedule?

No. The week-by-week amounts, frequency, final volume, syringe units, and supply calculations are preserved. New evidence language explains where the adult literature is limited without revising those values.

Is this peptide the same as growth hormone therapy?

No. One signals the pituitary to release endogenous GH; recombinant human growth hormone supplies the hormone directly. Their mechanisms, evidence bases, and clinical uses should not be treated as interchangeable.^[1][6]

What should happen after a missed administration?

This research page does not provide individualized missed-dose instructions. Do not double an amount to compensate. Product labeling and a qualified clinician are the appropriate sources for patient-specific directions.

General subcutaneous technique resources emphasize clean hands, a new sterile syringe, an appropriate site in the abdomen, thigh, or upper arm, and systematic site rotation. Prepare the skin, allow it to dry, insert at the angle appropriate for the needle and tissue depth, deliver the liquid steadily, and place the used device directly into a puncture-resistant sharps container.^[7][8][12]

Technique guidance does not validate the peptide amount or schedule. The concentration, U-100 conversion, and volume must still agree with the chart before any calculation is interpreted.

This page is an educational calculation and evidence reference, not medical advice or a recommendation for human use. Pediatric treatment evidence, adult stimulation studies, retrospective combination data, vial arithmetic, and community-style protocol examples answer different questions and should not be treated as interchangeable.

• 1
  
  PubMed
  — Prakash & Goa (1999): Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency (pediatric GHD; 30 µg/kg SC nightly; 6–12 month trials)

  View Source
• 2
  
  RxList
  — Sermorelin Acetate Injection Monograph: dosing (0.2–0.3 mg SC qHS adult off‑label); reconstitution/storage/administration guidelines

  View Source
• 3
  
  PubMed
  — Clinical studies: bedtime SC injection leverages natural nocturnal GH pulse; once‑daily nightly dosing yielded significant growth improvements in pediatric GHD over 6–12 months

  View Source
• 4
  
  Mayo Clinic
  — Sermorelin (injection route) – Proper Use and Storage: refrigerate reconstituted solution at 2–8 °C (36–46 °F); do not freeze; use within recommended period

  View Source
• 5
  
  RxList
  — Sermorelin Acetate Prescribing Information: adverse effects (injection‑site reactions ~17%; rare headache/flushing <1%); subclinical hypothyroidism ~6.5%; thyroid monitoring recommended

  View Source
• 6
  
  PubMed
  — Sermorelin mechanism: stimulates endogenous pulsatile GH via GHRH receptors; preserves physiologic feedback loops (somatostatin/IGF‑1 negative feedback); reduces overdose risk vs. exogenous GH

  View Source
• 7
  
  Johns Hopkins Arthritis Center
  — How to Give a Subcutaneous Injection: site selection (abdomen/thigh/arm); rotation guidelines; 45–90° angle; pinch technique; no aspiration; disposal in sharps container

  View Source
• 8
  
  CDC
  — Vaccine administration: subcutaneous route technique (45–90° angle; site prep; no aspiration for SC injections)

  View Source
• 9
  PubMed — Low-dose growth hormone-releasing hormone tests: adult dose-response study of GHRH(1-29)NH2 and acute GH secretion

  View Source
• 10
  PubMed — Retrospective adult report of IGF-1 during combined GHRP-6, GHRP-2, and sermorelin exposure; combination design limits sermorelin-specific conclusions

  View Source
• 11
  U.S. Food and Drug Administration — Orphan Drug Designations and Approvals record for sermorelin acetate (Geref) in pediatric growth hormone deficiency

  View Source
• 12
  NCBI Bookshelf — Best practices for parenteral injections, aseptic preparation, and administration technique

  View Source
• 13
  
  Pure Lab Peptides
  — Sermorelin 5 mg product page: high‑purity research‑grade peptide with batch COAs; quality and documentation standards

  View Source

Explore the available research context, protocol variants or comparisons, and practical guides. When vial-size variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.